- Between 2010 and 2017, coverage of PC in pre-SAC and SAC has steadily increased. Data collected from the 103 countries endemic for STH in 2017 show that the two Roadmap targets are well within reach by 2020
- Several countries have already completely eliminated STH morbidity (that is, morbidity caused almost exclusively by STH infections of moderate and heavy intensity)
- The group stressed the need to identify attainable targets that will: maintain the achievements obtained by on-going STH control programmes in the first decade; further expand the benefit to other groups at risk (i.e. WRA); promote the control of strongyloidiasis within STH control programmes, where warranted; align with the targets of other NTDs and with the Sustainable Development Goals(SDGs); take advantage of recent changes in the public health landscape reflecting the increased visibility of NTDs in the health arena; the familiarity of endemic countries with the principles of PC; and the engagement of pharmaceutical donors in covering the drug needs of additional groups at risk; highlight collaboration with WASH experts to reduce re-infection and the need for PC; and progressively promote sustainability of the STH control programmes by endemic countries by adapting the intervention to the new epidemiological situation resulting from the successful implementation of the control measures (see Figure 2).
- SAC: donations available since 2010 and continued until 2020 (albendazole). PreSAC: donations available since 2019 and continued until 2020 (mebendazole)
ls-type:: annotation
hl-page:: 9
hl-color:: yellow
id:: 662f680f-a77b-46a0-8742-5189721a5257
- No ivermectin donation for STH or prequalified generic ivermectin available
- Lymphatic filariasis (LF) is expected to be eliminated by 2025; therefore, no contribution is expected from GPELF thereafter.
ls-type:: annotation
hl-page:: 10
hl-color:: yellow
id:: 662f684b-73c6-428e-a7ba-3bfbee72a97b
- chieve and maintain elimination of STH morbidity in pre-SAC and SAC by 2030 Number of countries where prevalence of pre-SAC and SAC with STH infections of moderate and heavy intensity (M&HI)<2%
ls-type:: annotation
hl-page:: 11
hl-color:: yellow
id:: 662f686f-ea7f-426f-90c5-e35894eb0af2
- Reduce the number of tablets needed in PC for STH No. of anthelminthic tablets needed to deworm pre-SAC and SAC
